Anebulo Pharmaceuticals Company Insiders
ANEB Stock | USD 1.40 0.06 4.11% |
Anebulo Pharmaceuticals' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Anebulo Pharmaceuticals suggests that all insiders are extremely bullish. Anebulo Pharmaceuticals employs about 2 people. The company is managed by 5 executives with a total tenure of roughly 5 years, averaging almost 1.0 years of service per executive, having 0.4 employees per reported executive.
Anebulo Pharmaceuticals' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2021-12-17 | Aron R English | Acquired 400 @ 6.59 | View | ||
2021-12-14 | Aron R English | Acquired 412 @ 5.89 | View | ||
2021-12-02 | Aron R English | Acquired 13836 @ 5.3 | View |
Monitoring Anebulo Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Anebulo |
Anebulo Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.6597) % which means that it has lost $0.6597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.138) %, meaning that it created substantial loss on money invested by shareholders. Anebulo Pharmaceuticals' management efficiency ratios could be used to measure how well Anebulo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -2.11. The current year's Return On Capital Employed is expected to grow to -2.07. At present, Anebulo Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 510.5 K, whereas Total Assets are forecasted to decline to about 3.9 M.The current year's Common Stock Shares Outstanding is expected to grow to about 26.7 M, whereas Net Loss is projected to grow to (10 M).
Anebulo Pharmaceuticals Workforce Comparison
Anebulo Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 501. Anebulo Pharmaceuticals adds roughly 2.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Anebulo Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anebulo Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anebulo Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Anebulo Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kupchyk Areta over a week ago Disposition of 82290 shares by Kupchyk Areta of Anebulo Pharmaceuticals at 2.18 subject to Rule 16b-3 | ||
English Aron R. over a month ago Acquisition by English Aron R. of 714250 shares of Anebulo Pharmaceuticals at 7.0 subject to Rule 16b-3 | ||
Allen Simon over three months ago Insider Trading | ||
Aryeh Jason over three months ago Acquisition by Aryeh Jason of 2482 shares of Anebulo Pharmaceuticals at 2.1 subject to Rule 16b-3 | ||
22nw Fund, Lp over six months ago Acquisition by 22nw Fund, Lp of 1703577 shares of Anebulo Pharmaceuticals at 0.125 subject to Rule 16b-3 | ||
Kenneth Cundy over six months ago Acquisition by Kenneth Cundy of 72613 shares of Anebulo Pharmaceuticals subject to Rule 16b-3 | ||
Kenneth Cundy over six months ago Acquisition by Kenneth Cundy of 72613 shares of Anebulo Pharmaceuticals at 2.78 subject to Rule 16b-3 | ||
English Aron R over six months ago Acquisition by English Aron R of 300000 shares of Anebulo Pharmaceuticals subject to Rule 16b-3 |
Anebulo Pharmaceuticals Notable Stakeholders
An Anebulo Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Anebulo Pharmaceuticals often face trade-offs trying to please all of them. Anebulo Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Anebulo Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Richard Cunningham | CEO Director | Profile | |
Rex CFA | CFO Sec | Profile | |
Daniel George | Acting Officer | Profile | |
Scott Anderson | Head Affairs | Profile | |
Kenneth Cundy | Chief Officer | Profile |
About Anebulo Pharmaceuticals Management Performance
The success or failure of an entity such as Anebulo Pharmaceuticals often depends on how effective the management is. Anebulo Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Anebulo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Anebulo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (2.01) | (2.11) | |
Return On Capital Employed | (2.18) | (2.07) | |
Return On Assets | (2.01) | (2.11) | |
Return On Equity | (2.15) | (2.04) |
Please note, the presentation of Anebulo Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Anebulo Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Anebulo Pharmaceuticals' management manipulating its earnings.
Anebulo Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Anebulo Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Anebulo Pharmaceuticals within its industry.Anebulo Pharmaceuticals Manpower Efficiency
Return on Anebulo Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 4.1M | |
Net Loss Per Executive | 1.6M | |
Working Capital Per Employee | 1.6M | |
Working Capital Per Executive | 649.5K |
Complementary Tools for Anebulo Stock analysis
When running Anebulo Pharmaceuticals' price analysis, check to measure Anebulo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anebulo Pharmaceuticals is operating at the current time. Most of Anebulo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Anebulo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anebulo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Anebulo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |